MBX Biosciences (MBX) Change in Acquisitions & Divestments (2023 - 2026)

MBX Biosciences has reported Change in Acquisitions & Divestments for 4 years, with the latest figure at $57.5 million in Q1 2026.

• Quarterly Change in Acquisitions & Divestments rose 0.61% year-over-year to $57.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $268.2 million (up 138.1% YoY) and the FY2025 annual result came in at $267.9 million, up 235.89% from the prior year.
• Change in Acquisitions & Divestments fell to $57.5 million in Q1 2026 per MBX's latest filing, from $76.2 million in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $76.2 million in Q4 2025 and troughed at $5.0 million in Q4 2023.
• A 4-year average of $41.0 million and a median of $42.1 million in 2024 frame the typical range for Change in Acquisitions & Divestments.
• The sharpest annual moves came in 2025 and 2026: Change in Acquisitions & Divestments surged 786.33% in 2025, then rose 0.61% in 2026.
• Over 4 years, Change in Acquisitions & Divestments stood at $5.0 million in 2023, then jumped by 305.0% to $20.2 million in 2024, then soared by 276.54% to $76.2 million in 2025, then declined by 24.59% to $57.5 million in 2026.
• According to Business Quant data, Change in Acquisitions & Divestments over the past three periods registered $57.5 million, $76.2 million, and $61.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.